3160 Federal Register / Vol. 76, No. 12 / Wednesday, January 19, 2011 / Notices 

Web site: http://www.usdoj.gov/enrd/ 

Consent_Decrees.html. A copy of the 

proposed consent decree may also be 

obtained by mail from the Consent 

Decree Library, P.O. Box 7611, U.S. 

Department of Justice, Washington, DC 

20044–7611 or by faxing or e-mailing a 

request to Tonia Fleetwood 

(tonia.fleetwood@usdoj.gov), fax no. 

(202) 514–0097, phone confirmation 

number (202) 514–1547. In requesting a 

copy from the Consent Decree Library, 

please enclose a check in the amount of 

$26.50 (25 cents per page reproduction 

cost) payable to the U.S. Treasury or, if 

by e-mail or fax, forward a check in that 

amount to the Consent Decree Library at 

the stated address. 

Maureen M. Katz, 

Assistant Chief, Environmental Enforcement 

Section, Environment and Natural Resources 

Division. 

[FR Doc. 2011–973 Filed 1–18–11; 8:45 am] 

BILLING CODE 4410–15–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By Notice dated May 28, 2010 and 

published in the Federal Register on 

June 8, 2010, (75 FR 32504), Stepan 

Company, Natural Products Department, 

100 W. Hunter Avenue, Maywood, New 

Jersey 07607, made application by 

renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

an importer of Coca Leaves (9040), a 

basic class of controlled substance listed 

in schedule II. 

The company plans to import the 

listed controlled substance for the 

manufacture of a bulk controlled 

substance for distribution to its 

customer. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a) 

and determined that the registration of 

Stepan Company to import the basic 

class of controlled substance is 

consistent with the public interest and 

with United States obligations under 

international treaties, conventions, or 

protocols in effect on May 1, 1971. DEA 

has investigated Stepan Company to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic class of controlled substance 

listed. 

Dated: December 20, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–939 Filed 1–18–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances 

Notice of Registration 

By Notice dated May 28, 2010, and 

published in the Federal Register on 

June 8, 2010 (75 FR 32505), Meda 

Pharmaceuticals, Inc. 705 Eldorado 

Street, Decatur, Illinois 62523, made 

application by letter to the Drug 

Enforcement Administration (DEA) to 

be registered as an importer of Nabilone 

(7379), a basic class of controlled 

substance listed in schedule II. 

The company plans to import the 

listed controlled substance as a finished 

drug product in dosage form only for 

distribution to its customers. The 

company does not import the listed 

controlled substance in bulk active 

pharmaceutical ingredient (API) form. 

There are no domestic sources of 

Nabilone in finished drug product form 

available in the United States. The U.S. 

Food and Drug Administration has 

approved this product for medical use 

in the United States. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and § 952(a), 

and determined that the registration of 

Meda Pharmaceuticals Inc. to import the 

basic classes of controlled substances is 

consistent with the public interest, and 

with United States obligations under 

international treaties, conventions, or 

protocols in effect on May 1, 1971. DEA 

has investigated Meda Pharmaceuticals 

Inc. to ensure that the company’s 

registration is consistent with the public 

interest. The investigation has included 

inspection and testing of the company’s 

physical security systems, verification 

of the company’s compliance with state 

and local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and § 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic classes of controlled 

substances listed. 

Dated: December 20, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–942 Filed 1–18–11; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated April 20, 2010 and 

published in the Federal Register on 

April 26, 2010, (75 FR 21661), Stepan 

Company, Natural Products Department, 

100 W. Hunter Avenue, Maywood, New 

Jersey 07607, made application by 

renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

a bulk manufacturer of the basic classes 

of controlled substances: 

Drug Schedule 

Cocaine (9041) ............................. II 

Benzoylecgonine (9180) ............... II 

The company plans to manufacture 

the listed controlled substances in bulk 

for distribution to its customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Stepan Company to manufacture the 

listed basic classes of controlled 

substances is consistent with the public 

interest at this time. DEA has 

investigated Stepan Company to ensure 

that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: December 20, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2011–940 Filed 1–18–11; 8:45 am] 

BILLING CODE 4410–09–P 

mstockstill on DSKH9S0YB1PROD with NOTICES